1599. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN Jr, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN.
1597. Segmentation-based MR attenuation correction including bones also affects quantitation in brain study: an initial result of 18F-FP-CIT PET/MR for patients with Parkinsonism
Choi H, Cheon GJ, Kim HJ, Choi SH, Lee JS, Kim YI, Kang KW, Chung JK, Kim EE, Lee DS
1596. The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials
Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Kim EE, Lee DS, Chung JK